Financial Review: ContraFect (CFRX) versus Soligenix (SNGX)

ContraFect (NASDAQ: CFRX) and Soligenix (NASDAQ:SNGX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, risk, valuation, analyst recommendations and institutional ownership.


This table compares ContraFect and Soligenix’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
ContraFect N/A -84.07% -44.69%
Soligenix -90.93% -112.81% -71.98%

Earnings and Valuation

This table compares ContraFect and Soligenix’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
ContraFect N/A N/A -$28.53 million ($0.23) -3.91
Soligenix $10.45 million 1.71 -$3.24 million ($1.04) -1.97

Soligenix has higher revenue and earnings than ContraFect. ContraFect is trading at a lower price-to-earnings ratio than Soligenix, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

62.5% of ContraFect shares are held by institutional investors. Comparatively, 2.1% of Soligenix shares are held by institutional investors. 9.3% of ContraFect shares are held by company insiders. Comparatively, 5.0% of Soligenix shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Risk & Volatility

ContraFect has a beta of -0.85, indicating that its share price is 185% less volatile than the S&P 500. Comparatively, Soligenix has a beta of 2.18, indicating that its share price is 118% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and price targets for ContraFect and Soligenix, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ContraFect 0 1 0 0 2.00
Soligenix 0 0 2 0 3.00

Soligenix has a consensus target price of $5.25, suggesting a potential upside of 156.10%. Given Soligenix’s stronger consensus rating and higher possible upside, analysts clearly believe Soligenix is more favorable than ContraFect.

About ContraFect

ContraFect Corporation, a clinical-stage biotechnology company, focuses on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases in the United States. Its lead product candidates consist of CF-301, a lysin that completed Phase 1 human clinical trials for the treatment of Staph aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible Staph aureus; and CF-404, a combination of human monoclonal antibodies (mAbs) for the treatment of life-threatening seasonal and pandemic varieties of human influenza. The company has a collaboration research agreement with The Rockefeller University to identify new lysin therapeutic candidates targeting Gram-negative bacteria; and license agreement with Trellis Bioscience LLC for mAbs in the field of influenza. ContraFect Corporation was founded in 2008 and is headquartered in Yonkers, New York.

About Soligenix

Soligenix, Inc. is a late-stage biopharmaceutical company. The Company is focused on developing and commercializing products to treat rare diseases. The Company operates through two segments: BioTherapeutics and Vaccines/BioDefense. Its BioTherapeutics segment is developing a photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL), formulations of oral beclomethasone 17,21-dipropionate (BDP) for the prevention/treatment of gastrointestinal (GI) disorders characterized by severe inflammation, and its innate defense regulator (IDR) technology, dusquetide (SGX942) for the treatment of oral mucositis in head and neck cancer. Its Vaccines/BioDefense business segment includes active development programs for RiVax, its ricin toxin vaccine candidate, OrbeShield, its GI acute radiation syndrome (GI ARS) therapeutic candidate, and SGX943, its melioidosis therapeutic candidate.

Receive News & Ratings for ContraFect Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ContraFect Corporation and related companies with's FREE daily email newsletter.

Leave a Reply